Small Molecules in Hematology

Buch | Hardcover

VIII, 294 Seiten

2018 | 3rd ed. 2018
Springer International Publishing (Verlag)
978-3-319-91438-1 (ISBN)

Artikel merken

This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.

Uwe Martens, Prof. Dr. med., is chair of the Cancer Center Heilbronn-Franken and head of the Department of Hematology and Oncology at the SLK Clinic Heilbronn, which is an academic teaching hospital of the University of Heidelberg. He graduated in Medicine from the University of Freiburg and continued his medical and scientific training at the Medical University Center in Freiburg and at the BC Cancer Research Center in Vancouver. His scientific focus is the development of personalized cancer therapy and immunotherapy. He is a co-founder of the MOLIT Institute for Personalized Medicine at the science and technology park in Heilbronn, which aims to rapidly translate precision medicine into standard care.

Imatinib .- Dasatinib .- Nilotinib .- Bosutinib .- Ponatinib .- Ruxolitinib .- Ibrutinib .- Lenalidomide .- Pomalidomide .- Enasidenib .- Midostaurin .- Alectinib .- Osimertinib .- Venetoclax .- Idelaslisib .- Carfilzomib .- Acalabrutinib.

Erscheinungsdatum	18.08.2018
Reihe/Serie	Recent Results in Cancer Research
Zusatzinfo	VIII, 294 p. 28 illus., 17 illus. in color.
Verlagsort	Cham
Sprache	englisch
Maße	155 x 235 mm
Gewicht	619 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Hämatologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Schlagworte	Chemical Structurs • drug interactions • Molecular mechanisms of cancer • mTOR • Personalized Cancer Therapy • Proteasome • Protein Tyrosine Kinease Inhibitors • small molecules • targeted therapy • Treatment Applications
ISBN-10	3-319-91438-3 / 3319914383
ISBN-13	978-3-319-91438-1 / 9783319914381
Zustand	Neuware